Gilead Sciences, Inc.
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.33−0.35 (-0.21%)
Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%
Gilead Sciences Consolidated revenues by Year
Consolidated revenues — Japan (legacy breakout, $M) ($M)
Gilead Sciences Consolidated revenues: $2,527M in FY2016, up 30.6% from a year earlier. No newer figure appears in the documents we track.
Latest, FY2016
2,527
Period ended Dec 31, 2016
Change on a year earlier
+30.6%
1,935 in FY2015
History
3 years
Since FY2014
Sources
1
Form 10-K (filed 2017-02-27)
Where the FY2016 figure comes from
Source: Form 10-K (filed 2017-02-27) ↗
Reported in Form 10-K Segment & Geographic Information.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Consolidated revenues — Japan (legacy breakout, $M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2016 | Dec 31, 2016 | 2,527 | +30.6% | Form 10-K (filed 2017-02-27) ↗ |
| FY2015 | Dec 31, 2015 | 1,935 | +3,550.9% | Form 10-K (filed 2017-02-27) ↗ |
| FY2014 | Dec 31, 2014 | 53 | – | Form 10-K (filed 2017-02-27) ↗ |
Cite this data
StockData. (2026). Gilead Sciences Consolidated revenues ($M), annual FY2014–FY2016 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/geo-rev-jp
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.